BioSpace News Archive

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET.

BioVie Inc. announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald’s Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

CSL Seqirus, a business of CSL Limited, announced new data from two Canadian studies investigating influenza vaccination uptake, perceptions about influenza, and the importance of vaccination.

As part of their well-established partnership, the United Nations Institute for Training and Research and Takeda, a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies.

Genialis , a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced an update to its ResponderID platform, including major innovations to its data flywheel that optimizes the interoperability of datasets for disease modeling.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate.

Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced that Suso J. Platero , Ph.D. has joined the company as its chief scientific officer.

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA ® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).

Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced data on its CLAROMER drug discovery platform’s treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of pre-clinical in vitro and in vivo studies.

iXCells Biotechnologies announced receiving a growth investment from Connecticut-based Great Point Partners, a private investment firm focusing on the healthcare industry.